Table 3.
Patient‐Level Predictors of MRA Prescription in Ideal Candidatesa
| Comparison | Odds Ratio (95% CI) | F Value | P Value |
|---|---|---|---|
| Race | 7.67 | <0.001 | |
| Black vs white | 1.28 (1.13, 1.44) | ||
| Hospitalization year | 3.80 | <0.001 | |
| 2003 vs 2009 | 1.22 (0.79, 1.88) | ||
| 2004 vs 2009 | 1.30 (0.81, 2.09) | ||
| 2005 vs 2009 | 1.43 (1.21, 1.69) | ||
| 2006 vs 2009 | 1.12 (0.96, 1.31) | ||
| 2007 vs 2009 | 1.28 (1.10, 1.49) | ||
| 2008 vs 2009 | 1.12 (0.93, 1.36) | ||
| Age (per 1 year from mean) | 0.98 (0.98, 0.99) | 60.42 | <0.001 |
| Total comorbidities (per comorbidity)11 | 0.93 (0.90, 0.96) | 19.10 | <0.001 |
| Serum sodium, per mEq/L | 0.97 (0.96, 0.99) | 18.28 | <0.001 |
| Serum creatinine, per mg/dL | 0.81 (0.71, 0.92) | 10.93 | 0.001 |
| Body mass index, per kg/m2 | 1.01 (1.01, 1.02) | 11.42 | <0.001 |
| Systolic BP, admission (per mm Hg) | 0.993 (0.991, 0.995) | 43.84 | <0.001 |
| Hypertension (complicated) | 1.22 (1.06, 1.41) | 7.57 | 0.006 |
| Diabetes (uncomplicated) | 1.28 (1.15, 1.42) | 19.80 | <0.001 |
| Diabetes (complicated) | 1.17 (1.01, 1.36) | 4.51 | 0.03 |
| Liver disease | 1.86 (1.49, 2.31) | 30.40 | <0.001 |
| Metastatic cancer | 0.29 (0.15, 0.54) | 15.02 | <0.001 |
| Fluid and electrolyte disorders | 1.26 (1.12, 1.43) | 14.09 | <0.001 |
| Deficiency anemias | 1.18 (1.05, 1.33) | 7.60 | 0.006 |
| Drug abuse | 0.73 (0.59, 0.91) | 7.60 | 0.006 |
| Depression | 1.31 (1.13, 1.52) | 12.92 | <0.001 |
| Loop diuretic | 1.69 (1.29, 2.21) | 14.47 | <0.001 |
| Thiazide diuretic | 1.24 (1.09, 1.41) | 10.36 | 0.001 |
| Digoxin | 1.65 (1.50, 1.82) | 99.36 | <0.001 |
BP indicates blood pressure; MRA, mineralocorticoid receptor antagonist.
a
Adjusted for clustering within hospital.